US8313738B2 - Pharmaceutical composition for intracellular acidification with cis-urocanic acid - Google Patents

Pharmaceutical composition for intracellular acidification with cis-urocanic acid Download PDF

Info

Publication number
US8313738B2
US8313738B2 US10/534,988 US53498805A US8313738B2 US 8313738 B2 US8313738 B2 US 8313738B2 US 53498805 A US53498805 A US 53498805A US 8313738 B2 US8313738 B2 US 8313738B2
Authority
US
United States
Prior art keywords
uca
cis
cells
trans
cytosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/534,988
Other languages
English (en)
Other versions
US20060035973A1 (en
Inventor
Lasse Leino
Jarmo Laihia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocis Pharma Oy
Original Assignee
Biocis Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocis Pharma Oy filed Critical Biocis Pharma Oy
Assigned to BIOCIS PHARMA OY reassignment BIOCIS PHARMA OY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAIHIA, JARMO, LEINO, LASSE
Publication of US20060035973A1 publication Critical patent/US20060035973A1/en
Priority to US13/584,999 priority Critical patent/US8673281B2/en
Priority to US13/651,555 priority patent/US8673280B2/en
Application granted granted Critical
Publication of US8313738B2 publication Critical patent/US8313738B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to the use of a pharmaceutically acceptable agent for acidifying cell cytoplasm and subsequently causing immunosuppression in a person or an animal, and to treatment or prevention of diseases or disorders, curable by immunosuppression.
  • the invention relates also to a novel pharmaceutical composition, comprising a pharmaceutically acceptable agent being able to acidify the cell cytoplasm and subsequently cause immunosuppression in the person or the animal.
  • UVB ultraviolet B
  • the agents responsible for direct absorption of the UVB photons in epidermis include urocanic acid (UCA) and DNA. Endogenous trans-UCA, synthesized by enzymatic deamination of histidine in the stratum corneum of the skin, is directly photoisomerized to cis-UCA upon exposure to UVB radiation.
  • UCA is capable of modulating certain functions in isolated cells of the immune system in vitro, such as antigen presentation (Beissert 1997, Holá ⁇ hacek over (n) ⁇ 1998), NK-cell cytotoxicity (Gilmour 1993, Uksila 1994), cytokine production by spleen cells (Holá ⁇ hacek over (n) ⁇ 1998), degranulation of mast cells (Wille 1999) and activation of neutrophils (Kivistö 1996).
  • the inventors of the present invention have demonstrated a so far unknown mechanism of action of cis-urocanic acid. They have surprisingly shown that cis-urocanic acid migrates into the cell cytosol in a form which is able to release a proton in the cytosol, subsequently acidify the cytoplasm, and as a result thereof, act as an immunosuppressing agent.
  • this invention relates to the use of a pharmaceutically acceptable agent or salt thereof being able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or an animal, wherein an effective amount of said agent is administered in an essentially non-dissociated form to the person or animal, and wherein the agent is admixed with a carrier adjusting the pH of the composition to the pH range 6.1 to 7.0.
  • the invention concerns a pharmaceutical composition
  • a pharmaceutical composition comprising as active substance a pharmaceutically acceptable agent or salt thereof being able to acidify the cell cytoplasm, in combination with a pharmaceutically acceptable carrier, which carrier essentially prevents the agent from dissociating at extracellular pH values and wherein the carrier is able to keep the pH of the composition in the range 6.1 to 7.0.
  • FIG. 1 is a scheme for the chemical synthesis of [ 14 C]-radiolabeled trans- and cis-UCA.
  • FIG. 2 shows accumulation of UCA to live neutrophils.
  • the data points represent the mean ⁇ SEM in duplicate tubes after subtracting the blank value.
  • the cells 7.0 ⁇ 10 6 cells/ml HBSS
  • the cells were incubated with the [ 14 C]UCA isomers at 4° C. for 30 min, washed, and transferred into scintillation vials.
  • Control vials without cells designated as “total UCA”, underwent a similar incubation to eliminate any non-specific binding effect by the incubation tubes. Hatched symbols, Estimated cpm values have been used for total UCA samples with >10 7 cpm due to technical maximum count limit.
  • FIG. 3 shows displacement of [ 14 C]cis-UCA incorporation by non-labeled cis-UCA.
  • Neutrophils isolated from freshly drawn venous blood of a single volunteer were assayed at two occasions (seven days apart) for displacement at pH 7.4.
  • the cells (7.4 ⁇ 10 6 /ml in Exp 1 and 6.3 ⁇ 10 6 /ml in Exp 2) were incubated in HBSS containing 1 mM [ 14 C]cis-UCA with or without 10 mM non-labeled cis-UCA (total volume 200 ⁇ l) at the indicated temperatures for 1 h.
  • the cells were washed after incubation as a pellet only, whereas the cells were resuspended in washing medium (HBSS) in Exp 2.
  • the data are from triplicate incubations.
  • FIG. 4 shows the distribution of incorporated cis-UCA in cellular fractions and by incubation temperature.
  • Neutrophils 50-200 ⁇ 10 6 cells/ml isolated from buffy coats were incubated with 1 or 5 mM [ 14 C]cis-UCA at 4° C. for 20-30 min. The cells were disrupted by sonication, the cellular fractions were separated by sucrose ultracentrifugation, and the bound activity was measured in each fraction.
  • FIG. 5 shows the elution of cytosol-associated [ 14 C]UCA in S-200 gel filtration.
  • Neutrophils 160-190 ⁇ 10 6
  • the cytosolic fraction was applied to the gel, and the protein content and UCA activity were measured in the elute.
  • A Cytosol of cells incubated with [ 14 C]cis-UCA.
  • B Cytosol of cells incubated with [ 14 C]trans-UCA.
  • C Elution of standard molecular weight protein markers and cis-UCA alone in the same conditions.
  • FIG. 6 shows lack of UCA metabolism in the experimental conditions.
  • Cytosolic proteins of [ 14 C]UCA-labeled neutrophils from various binding assays were precipitated with 10% TCA on ice overnight.
  • the amount of radioactive label was measured in the precipitate and protein-free supernatant by scintillation counting and the content of intact (non-metabolized) UCA isomers in the supernatant by HPLC.
  • FIG. 7 shows the pH effect of UCA isomers on standard incubation buffers. The pH was measured in PBS, pH 7.0 (A), and in HBSS buffers, pH 7.4 (B), containing graded concentrations of cis-UCA and trans-UCA.
  • FIG. 8 shows the relation of respiratory burst activity and acidification of the cytosol by UCA isomers.
  • neutrophils were incubated with 3 mM cis- or trans-UCA and analyzed simultaneously for respiratory burst chemiluminescence and pH indicator fluorescence.
  • A. Intracellular pH indicator dye fluorescence compared to control levels at the same extracellular pH. The cells were loaded with BCECF, washed, incubated with UCA, and analyzed with flow cytometry. The percentages have been calculated from the geometrical mean fluorescence intensities.
  • B Respiratory burst responses compared to control levels without UCA at the same pH. The results are from two parallel assays within each of the three experiments.
  • FIG. 9 shows the intracellular pH calibration in UCA-treated neutrophils in situ.
  • BCECF-labelled cells were used as pH reference cells after treatment with proton ionophore nigericin in high-potassium Pipes buffer at various pH.
  • Other BCECF-labelled cells were incubated with or without 3 mM UCA in low-potassium Pipes buffer adjusted to the same pH levels as those of the calibration buffers.
  • Intracellular pH was calculated using BCECF median fluorescence intensity obtained in flow cytometry.
  • the pharmaceutically acceptable agent is an acid having its dissociation constant in the range 6.7 to 7.4, preferably in the range 6.9 to 7.3; most preferably about 7.0.
  • the acid is preferably cis-urocanic acid or salt thereof, but it is not restricted hereto. Any other pharmaceutically acceptable, non-toxic agent having its dissociation constant in the range defined above and being able to accumulate inside a cell would be useful.
  • Such agents may be inorganic or organic, preferably an organic acid having, like cis-urocanic acid, a heterocyclic ring to which a saturated, or more preferably, an unsaturated carboxylic acid moiety is attached.
  • the heterocyclic group may be, for example, an imidazole (as for cis-urocanic acid) or any other heterocyclic or poly-heterocyclic group having the ability to donate a proton at cytoplasmic pH and thereby acidify the cytoplasm.
  • suitable heterocyclic groups can be mentioned thiazole, thiophene, furan, oxazole, triazole, tetrazole, pyrazole, pyridine, pyrimidine and triazine.
  • the pharmaceutically acceptable agent is admixed with a carrier, which can be one single component, or more preferably, a mixture of two or more components.
  • a carrier which can be one single component, or more preferably, a mixture of two or more components.
  • One of the components is suitably a buffering agent, which adjusts the pH of the composition to the desired value.
  • cis-urocanic acid is the active agent, it is preferable to adjust the pH of the composition to 6.5 to 7.0, preferably 6.7 to 7.0. In this pH range, cis-urocanic acid is still non-dissociated, while trans-urocanic acid is fully dissociated. Such a composition will therefore be specific with respect to cis-urocanic acid.
  • suitable buffering agents to adjust pH to 6.5-7.0 can be mentioned 50 mM sodium phosphate supplemented with 55 mM sodium chloride, 50 mM sodium citrate supplemented with 120 mM sodium chloride, and 10 mM Pipes supplemented with 133 mM sodium chloride.
  • the method and composition according to this invention is useful for treatment or prevention of any disease or disorder curable by increased immunosuppression.
  • immunosuppression used herein refers to regulation, typically down-regulation, of the body's immune system by affecting to the activity and function of the cells of the immune system in a way which prevents the undesired adverse effects of an immune response.
  • target cells of the method and compositions of the present invention are granulocytes (neutrophils, eosinophils, basophils), NK-cells, T- and B-lymphocytes, monocytes, macrophages, mast-cells and antigen presenting cells, such as dendritic cells, and their precursor cells and specific functional and phenotypic subsets.
  • the target cells of the method and compositions of the present invention are cells of the innate immune system, such as neutrophils and NK-cells.
  • immune cells recognize, isolate and eliminate locally infectious/damaging agents in a well-orchestrated process.
  • the immune cells are armed with various biochemical response mechanisms, which become active during the infectious attack.
  • neutrophilic leukocytes, neutrophils contain a highly specific enzyme complex, NADPH oxidase system, which, when triggered upon cell activation, is able to generate large amount of toxic oxygen metabolites, which can exert a number of damaging effects against biological material, and may also act as proinflammatory signals for other cells types.
  • leukocyte activation leads to a local inflammatory reaction which is an essential part of host's immune response and which promotes the resolution of the infectious assault and initiates the healing process.
  • normal host tissues are inappropriately identified as foreign or damaged structures, or due to the hyperactivation of host's immune system associated with some pathological states, normal tissue is attacked by immune cells which elicit their full destructive potential against host itself.
  • groups of conditions such as local and systemic inflammatory diseases, autoimmune diseases and allergic conditions.
  • hypersensitivity reactions such as contact hypersensitivity or delayed type hypersensitivity.
  • the condition which can be treated or prevented by the method and compositions of this invention is a local or systemic inflammatory reaction which involves the activation of the preferable target cells, such as inflammatory conditions of the skin, including psoriasis, acute or chronic dermatitis; inflammatory conditions of mucous membranes or the connective tissue of the oral cavity, eyes and genitals, such as periodontitis, conjunctivitis, vaginitis; inflammatory conditions of mammary glands, including mastitis; or any other local or systemic condition manifesting a recognized inflammatory component in the disease pathogenesis or progression, such as vasculitis, acute graft rejection, chronic obstructive pulmonary disease, asthma, reperfusion injury, and sepsis associated tissue damage.
  • the conditions that can be treated or prevented according to this invention are not restricted to the aforementioned examples.
  • the pharmaceutically acceptable agent can be administered by various routes, either systemically or locally.
  • suitable administration forms include, for example, oral formulations; parenteral injections including intravenous, intramuscular, intradermal and subcutaneous injections; and mucosal, topical, transdermal, inhalation, nasal or rectal formulations.
  • Particularly suitable formulations are formulations for local delivery such as topical formulations in the form of ointments, gels, creams, pastes, solutions, suspensions, lotions and emulsions.
  • the required dosage of the pharmaceutically acceptable agent will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed.
  • the amount of the pharmaceutically acceptable acid can typically range from 0.01% to 50%, preferably in the range 0.1 to 10%.
  • UCA radiolabeled UCA
  • a model cell the human peripheral blood neutrophil
  • UCA has been show to be affected by UCA
  • Urocanic acid is an UV radiation-absorbing substance in the mammalian skin.
  • the cis-UCA is an immunosuppressant in animal models in vivo, but the target cell type(s) and mode(s) of action have remained obscure.
  • Trans-urocanic acid 3-(1H-imidazol-4-yl)-2-propenoic acid
  • Sigma Sigma (St. Louis, Mo., USA).
  • Cis-UCA was prepared from trans-UCA with UV photoisomerization (see below).
  • the chemical purity of the UCA isomers was above 99.7% by high-pressure liquid chromatography (HPLC).
  • FIG. 1 The synthesis of [ 14 C]-radiolabeled trans- and cis-UCA is outlined in FIG. 1 .
  • trans-UCA (6) (138 mg, 1 mmol) was dissolved in water (500 ml). The solution was brought to pH 9 with solid potassium hydroxide and then irradiated under nitrogen atmosphere at 10° C. for 4 h. Photoisomerization was performed in a Normag falling-film photoreactor with Hanau quartz mercury high-pressure lamp (500 W, 270-350 nm, water as solvent). The resulting mixture (trans/cis ca. 30/70 by HPLC) was evaporated to dryness and the residue dissolved in 12.5 mM acetic acid.
  • Cis-UCA appeared after ca. 1100 ml and trans-UCA mainly after 1300 ml eluent volumes. Removal of the solvent from the fractions, followed by washing with diethyl ether and drying in vacuo at 65° C. over phosphorus pentoxide, yielded the pure [ 14 C]trans- and [ 14 C]cis-isomers (6) and (7).
  • the yield of (6) from the preceding step was 35 mg (25%), mp. 226° C.
  • the chemical purity of the product (6) by HPLC was above 99.8%, and the specific activity was 2.2 mCi/mmol.
  • the corresponding yield of (7) was 85 mg (58%), mp. 176-178° C.
  • HPLC analysis indicated the material to be more than 99.5% chemically pure with a specific activity of 5.8 mCi/mmol.
  • the radiolabeled and non-labeled cis- and trans-isomers were dissolved directly in the incubation buffers up to 100 mM and 30 mA concentrations, respectively. The dissolution of trans-UCA was aided with gentle warming in a water bath when needed.
  • Peripheral blood neutrophils were isolated from heparinized blood or buffy coats of healthy donors. Erythrocytes were sedimented with 6% dextran T-500 (Pharmacia, Sweden). Neutrophils were separated from the leukocyte-rich dextran plasma by centrifugation on Ficoll-Hypaque (Pharmacia), purified by hypotonic lysis of remaining erythrocytes, and washed with Ca- and Mg-free HBSS. For the intracellular pH experiments, neutrophils were prepared without erythrocyte lysis. The cells, media and centrifuges were kept at room temperature during cell preparation to avoid temperature fluctuations.
  • the respiratory burst activity was used as a measure of neutrophil function.
  • the UCA isomers were tested in a chemiluminescence assay with opsonized zymosan as described (Kivistö et al. 1996). The peak values were recorded.
  • Isolated neutrophils were resuspended in HBSS, pH 7.4, at 2-10 ⁇ 10 6 cells/ml.
  • the [ 14 C]cis- or [ 14 C]trans-UCA stock solutions were added to yield a concentration range 0.1 ⁇ M-30 mM, and the tubes, in duplicate, were incubated at 4° C. (or at 25° C. and 37° C.) for 30 min. The cells were then washed once with ice-cold HBSS and transferred into liquid scintillation vials.
  • the total [ 14 C]UCA activity in the incubation tubes was determined by measuring samples from each standard concentration, and blank scintillation values were subtracted before data analysis.
  • the localization of the cell-bound UCA in membrane, cytosol and nucleus was investigated after the incubation of whole cells with [ 14 C]cis-UCA as described above. After washing with HBSS, the cells were suspended (200 ⁇ 10 6 cells/ml) in ice-cold lysis buffer containing 10 mM Pipes, 10 mM KCl, 3 mM NaCl, 4 mM MgCl 2 , pH 7.0, supplemented with 0.5 mM PMSF, 10 ⁇ M leupeptin, and 10 ⁇ M pepstatin A (all from Sigma) as proteinase inhibitors. The cell membranes were broken by sonication on ice.
  • the lysate was centrifuged (800 ⁇ g, 25° C., 10 min), and the post-nuclear supernatant was layered on discontinuous cushions of sucrose in lysis buffer. After ultracentrifugation (120 000 ⁇ g, 4° C., 45 min), the cytosol, membrane, and nuclei/debris fractions were recovered by careful pipetting, and [ 14 C] activity was measured.
  • the sample (0.5-2.5 ml) was applied to the balanced Sephacryl S-200 gel filtration (Pharmacia) column at 4° C., and the proteins were eluted with PBS, pH 7.0, at a flow rate of about 0.6 ml/min.
  • the elution of proteins was followed with a flow-through UV monitor at 254 nm and a potentiometric recorder.
  • a typical run consisted of thirty 6-ml fractions and lasted for almost six hours.
  • the elution volumes of proteins of different molecular weights were determined with a cocktail of standard proteins and peptides of 0.6-2000 kDa size.
  • Protein concentration was determined with Bio-Rad (Munich, Germany) protein assay using bovine albumin as a standard.
  • Intracellular pH levels in neutrophils were monitored with flow cytometry utilizing a pH-sensitive fluorescent dye 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF, acetoxymethyl ester; Molecular Probes, Leiden, The Netherlands). About 30 ⁇ 10 6 cells were incubated in 10 ml HBSS, pH 7.4, containing 0.35 ⁇ M BCECF at 25° C. for 30 min, washed twice in HBSS, and resuspended in 1 ml of 154 mM NaCl.
  • BCECF pH-sensitive fluorescent dye 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein
  • Radioactive, [ 14 C]-labeled UCA isomers were synthesized to examine the binding of UCA to isolated human peripheral blood neutrophils.
  • the cells incubated with UCA in HBSS at 4° C. for 30 min, incorporated both isomers in a linear dose-dependent manner over the studied concentration range of 100 nM to 30 mM ( FIG. 2 ).
  • An interesting feature of this uptake was that we were unable to demonstrate displacement of the [ 14 C]UCA radiolabel with non-labeled (“cold”) UCA as one would expect in conventional ligand-receptor binding ( FIG. 3 ).
  • the remaining cell-bound cis-UCA (5.3% ⁇ 2.1%) was detected in the nuclear (and possibly non-lysed cell) fraction of the cell lysate ( FIG. 4A ).
  • FIG. 8A shows data from three independent experiments measuring simultaneously BCECF signals and respiratory burst activity of the cells (see below).
  • a fourth experiment was performed for intracellular BCECF fluorescence measurement only.
  • cis-UCA suppressed the respiratory burst activity by 15% ⁇ 8.4% and 44% ⁇ 1.3%, respectively.
  • trans-UCA inhibited the chemiluminescence by 31% ⁇ 8.4% and 48% ⁇ 4.0% at pH 6.22 ⁇ 0.02 (nominal pH 7.4) and 5.87 ⁇ 0.06 (nominal pH 6.5), respectively.
  • the corresponding inhibitions for cis-UCA were 41% ⁇ 10% at pH 6.60 ⁇ 0.02 (nominal pH 7.4) and 48% ⁇ 1.6% at pH 6.33 ⁇ 0.07 (nominal pH 6.5).
  • UCA is a weak organic acid
  • the accumulation of UCA inside the cell could regulate the cytosolic pH. This, however, greatly depends on the protonation status of the entering UCA molecules.
  • UCA is a polyprotic acid with two proton-donor moieties, the carboxyl group and the imidazolyl group.
  • the pK a of the carboxyl group is 4.0 for trans-UCA and 3.3 for cis-UCA (Roberts 1982), from which it follows that practically all UCA molecules are deprotonated at the carboxyl group at pH above 4, according to the Henderson-Hasselbalch Equation (H-H Eq.).
  • the protonation status of the imidazolyl group alone determines whether the molecule is able to donate a proton and thereby promote acidification.
  • the imidazolyl pK a of trans-UCA is 6.1 (Roberts et al. 1982, Krien & Kermici 2000) while for cis-UCA it is markedly higher, 7.0, potentially due to the stabilized tautomeric form of the cis-isomer caused by intramolecular hydrogen bonding between the carboxyl and imidazolyl moieties (Roberts 1982).
  • the invention is further illuminated by the following non-restricting Examples.
  • Cream Composition 1 (% w/w) Cis-urocanic acid 0.1-10 Propylene glycol 50 Cetostearyl alcohol 15 Sodium lauryl sulfate 1 Buffering agent 0.01-1 Purified water to 100
  • Cream Composition 2 (% w/w) Cis-urocanic acid 0.1-10 Cetostearyl alcohol 6.75 Propylene glycol 40 Sodium lauryl sulphate 0.75 Poloxamer 407 1 Mineral oil 5 Stringy petrolatum 12. 5 Buffering agent 0.01-1 Purified water to 100
  • Oinment Composition (% w/w) Cis-urocanic acid 0.1-10 Mineral oil 5 Buffering agent 0.01-1 Petrolatum to 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/534,988 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic acid Expired - Fee Related US8313738B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/584,999 US8673281B2 (en) 2003-03-14 2012-08-14 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US13/651,555 US8673280B2 (en) 2003-03-14 2012-10-15 Pharmaceutical composition for intracellar acidification with cis-urocanic acid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FI20030379 2003-03-14
FIFI20030379 2003-03-14
FI20030379A FI20030379A0 (fi) 2003-03-14 2003-03-14 Uusi farmaseuttinen koostumus
PCT/FI2004/000109 WO2004080456A1 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/584,999 Division US8673281B2 (en) 2003-03-14 2012-08-14 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US13/651,555 Continuation US8673280B2 (en) 2003-03-14 2012-10-15 Pharmaceutical composition for intracellar acidification with cis-urocanic acid

Publications (2)

Publication Number Publication Date
US20060035973A1 US20060035973A1 (en) 2006-02-16
US8313738B2 true US8313738B2 (en) 2012-11-20

Family

ID=8565804

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/534,988 Expired - Fee Related US8313738B2 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US13/584,999 Expired - Fee Related US8673281B2 (en) 2003-03-14 2012-08-14 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US13/651,555 Expired - Fee Related US8673280B2 (en) 2003-03-14 2012-10-15 Pharmaceutical composition for intracellar acidification with cis-urocanic acid

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/584,999 Expired - Fee Related US8673281B2 (en) 2003-03-14 2012-08-14 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US13/651,555 Expired - Fee Related US8673280B2 (en) 2003-03-14 2012-10-15 Pharmaceutical composition for intracellar acidification with cis-urocanic acid

Country Status (14)

Country Link
US (3) US8313738B2 (pt)
EP (2) EP2014289A1 (pt)
JP (2) JP5398954B2 (pt)
AT (1) ATE386515T1 (pt)
AU (1) AU2004218944B2 (pt)
CA (1) CA2518885C (pt)
CY (1) CY1107346T1 (pt)
DE (1) DE602004011906T2 (pt)
DK (1) DK1603559T3 (pt)
ES (1) ES2299823T3 (pt)
FI (1) FI20030379A0 (pt)
PL (1) PL1603559T3 (pt)
PT (1) PT1603559E (pt)
WO (1) WO2004080456A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20031793A0 (fi) 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus
JP5756615B2 (ja) * 2010-11-02 2015-07-29 花王株式会社 オートインデューサー−２阻害剤、並びに歯周病又は齲蝕病の予防及び／又は治療剤
WO2021181711A1 (ja) * 2020-03-10 2021-09-16 均 石井 アレルギー治療薬

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794106A (en) * 1983-01-31 1988-12-27 Taisho Pharmaceutical Co., Ltd. Cream
DE4121030A1 (de) 1990-06-29 1992-01-02 Beiersdorf Ag Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsaeure
DE4122497A1 (de) 1991-07-02 1993-01-21 Optimum Patentverwertungsgesel Verfahren zur herstellung eines mittels zur externen anwendung und zusammen mit uv-lichtbestrahlung bei entzuendlichen hauterkrankungen
EP0612525A1 (en) 1993-02-25 1994-08-31 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5494676A (en) * 1990-06-29 1996-02-27 Bode Chemie Dermatological compositions containing CIS-urocaninic acid
US5686100A (en) 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5995869A (en) * 1996-06-12 1999-11-30 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
US6028098A (en) 1993-03-29 2000-02-22 Bioglan Ireland (R&D) Limited Use of cis-or transurocamic acid for the treatment of photodermatoses and immunogenic skin diseases
US6153176A (en) * 1995-01-20 2000-11-28 The Procter & Gamble Company Low pH sunscreen compositions
WO2002007520A2 (en) * 2000-07-20 2002-01-31 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6372199B1 (en) 1998-04-18 2002-04-16 Beiersdorf Ag Use of unsymmetrically substituted triazine derivatives in cosmetic or dermatological preparations for maintaining the urocanic acid status of the skin
US20020111362A1 (en) 1999-10-15 2002-08-15 Joseph Rubinfeld Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876765A (en) * 1968-05-03 1975-04-08 Choay Sa Pharmaceutical composition containing vitamin b' 12', process of making the same and method of treatment therewith
US6310067B1 (en) * 1998-02-05 2001-10-30 Senju Pharmaceutical Co., Ltd. Urocanic acid derivatives
FI20031793A0 (fi) * 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794106A (en) * 1983-01-31 1988-12-27 Taisho Pharmaceutical Co., Ltd. Cream
DE4121030A1 (de) 1990-06-29 1992-01-02 Beiersdorf Ag Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsaeure
EP0467116A1 (de) 1990-06-29 1992-01-22 Bode Chemie GmbH & Co. Dermatologische Zusammensetzungen mit einem Gehalt an cis-Urocaninsäure
US5494676A (en) * 1990-06-29 1996-02-27 Bode Chemie Dermatological compositions containing CIS-urocaninic acid
DE4122497A1 (de) 1991-07-02 1993-01-21 Optimum Patentverwertungsgesel Verfahren zur herstellung eines mittels zur externen anwendung und zusammen mit uv-lichtbestrahlung bei entzuendlichen hauterkrankungen
EP0612525A1 (en) 1993-02-25 1994-08-31 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US6028098A (en) 1993-03-29 2000-02-22 Bioglan Ireland (R&D) Limited Use of cis-or transurocamic acid for the treatment of photodermatoses and immunogenic skin diseases
US5686100A (en) 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5912010A (en) * 1994-11-22 1999-06-15 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US6153176A (en) * 1995-01-20 2000-11-28 The Procter & Gamble Company Low pH sunscreen compositions
US5995869A (en) * 1996-06-12 1999-11-30 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
US6372199B1 (en) 1998-04-18 2002-04-16 Beiersdorf Ag Use of unsymmetrically substituted triazine derivatives in cosmetic or dermatological preparations for maintaining the urocanic acid status of the skin
US20020111362A1 (en) 1999-10-15 2002-08-15 Joseph Rubinfeld Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
WO2002007520A2 (en) * 2000-07-20 2002-01-31 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
Antoine et al., "pH Influence of Surfactant-induced Skin Irritation," 37 Derm. Beruf. Umwelt. 96 (1989).
Baranda et al. (International Journal of Dermatology (2002); 41:494-499). *
Ben-Basset et al. ("Inhibitors of Tyrosine Kinases in the Treatment of Psoriasis"; Current Pharmaceutical Design, 2000, vol. 6 No. 9: 933-942). *
Berner et al., "The Relationship between pKa and Skin Irritation for Series of Basic Penetrants in Man," 15 Fund. Applied. Toxic. 760 (1990).
Bettley et al., "The Irritant Effect of Soap upon the Normal Skin," 72 Br. J. Dermatol. 67 (1960).
Burobin et al., "Biological Activity of Urocanic Acid," 31 Voprosy Meditsinskoi Khimii 102 (1985) with Translation.
Butcher et al., "Irritant Actions of Unphysiological pH Values. A Controlled Procedure to Test for Topical Irritancy," 9 Agents Action 124 (1979).
Cho et al., "Effect of the pH in Soaps on Skin Irritation," 4 Korean J. Invest. Dermatol, 124 (1997).
Goosens, "Allergy and Hypoallergenic Products", Chapter 53 of Handbook of Cosmetic Science and Technology ( 3rd ed., Barel et. al. eds., 2009).
Granstein Psoriasis: Further Evidence of a Key Role for Leukocytes. J. Clin. Invest. vol. 98, No. 8, Oct. 1996, 1695-1696. *
Guillot et al., "Evaluation of the Cutaneous-Irritation Potential of 56 Compounds," 20 Fd. Chem . Toxic. 563 (1982).
Halvarsson et al., "Increasing Quality of Life by Improving the Quality of Skin in Patients with Atopic Dermatitis," 29 Int. J. Cosmet. Sci. 69 (2007).
Holmes, "Paclitaxel combination Therapy in the Treatment of Metastatic Breast Cancer," 23 Seminars in Oncology 29 (1996).
http://www.sigmaaldrich.com/lifescience/corebioreagents/biological-buffers/learining-center/buffer-reference-center.html, Feb. 26, 2009.
Johansen, "Fragrance Contact Allergy," 4 Am. J. Clin. Dermatol. 789 (2003).
Korting et al., "Influence of Skin Cleansing Preparation Acidity on Skin Surface Properties," 13 Int. J. Cosmet. Sci., 91 (1991).
Lakshmi et al., "Irritancy Ranking of 31 Cleansers in the Indian Market in a 24-h Patch Test," 30 Int. J. Comet. Sci. 277 (2008).
Mastitis. The American Heritage Stedman's Medical Dictionary (2002). Retrieved Sep. 11, 2006, from xreferplus. http://www.xreferplus.com/entry/2785531. *
McKinney et al., "Irritant Action of Binary Soaps Mixtures on Skin," Oil & Soap 198 (1940).
Mohammad et al, "Invited Review: Urocanic Acid Photochemistry and Photobiology," 69 Photochemistry and Photobiology. 115 (1999).
MR Prater. "Immunotoxicity of Dermal Permethrin and CIS-Urocanic Acid: Effects of Chemical Mixtures in Environmental Health." PhD Thesis, Virginia Polytechnic Institute and State University, Mar. 8, 2002, pp. i-x and 1-191. *
Murahata et al., "Effect of pH on the Production of Irritation in a Chamber Irritation Test," 18 J. Am. Acad. Dermatol. 62 (1988).
Oestreicher, "Detergents, Bath Preparations, and Other Skin Cleansers," 6 Clin. Dermato. 29 (1998).
Paye "Mechanisms of Skin Irritation by Surfactants and Anti-Irritants for Surfactant-Based Products," chapter 43 of Handbook of Cosmetic Science and Technology (3rd ed., Barel et al. eds. 2009).
Purdue University, "pH, pOH, and Ka." http://chemed.chem.purdue.edu/genchem/topicreview/bp/ch17/ph.php, Feb. 23, 2006 (as of internet archive), 9 pages. *
Roberts, "A Nitrogen-15 Nuclear Magnetic Resonance Study of the Acid-Base and Tautomeric Equilibria of 4-Substituted Imidazoles and Its Relevance to the Catalytic Mechanism of a-Lytic Protease," 104 J.Am.Chem.Soc. 3945 (1982).
Schultz et al., "Inhibitors of Glutathione S-transferases as Therapeutic Agents," 26 Advanced Drug Delivery Reviews 91(1997).
Singh et al., "Comparative Measurement of Irritant Properties of Toilet bar Soaps on Human Skin," 56 Indian J. Dermatol. Venereol. Leprol. 67 (1990).
Stephenson, "Inflammation", General and Systematic Pathology 199 (J.C.E. Underwood and S.S. Cross eds., 5th ed. 2009).
STN Registry Database: Property Data for AG 18. *
T Mohammad, H Morrison, H HogenEsch. "Urocanic Acid Photochemistry and Photobiology." Photochemistry and Photobiology, 6(2), 1999, pp. 115-135. *
Tew et al., "Ethacrynic Acid and Piriprost as Enhancers of Cytotoxicity in Drug Resistant and Sensitive Cell Lines," 48 Cancer Research 3622 (1988).
Timm-Knudson at al., "Allergic Contact Dermatitis to Preservations," 18 Dermatol. Nursing 130 (2006).
Van Der Valk et al., "Skin Irritancy of Surfactants As Assessed by Water Vapor Loss Measurements," 82 J. Invest. Dermatol. 291 (1984).
Yuan et al., "Effects and Mechanisms of Aloperine on 2,4-Dinitrofluorobenzene-induced Allergic Contact Dermatitis in BALB/c Mice," 629 European J. of Pharmacology 147 (2010).

Also Published As

Publication number Publication date
DE602004011906D1 (de) 2008-04-03
CY1107346T1 (el) 2012-12-19
EP1603559B1 (en) 2008-02-20
US20060035973A1 (en) 2006-02-16
PT1603559E (pt) 2008-03-11
JP5398954B2 (ja) 2014-01-29
CA2518885A1 (en) 2004-09-23
AU2004218944B2 (en) 2009-10-08
CA2518885C (en) 2011-08-02
DE602004011906T2 (de) 2009-02-26
ATE386515T1 (de) 2008-03-15
EP1603559A1 (en) 2005-12-14
US20120315299A1 (en) 2012-12-13
US8673281B2 (en) 2014-03-18
EP2014289A1 (en) 2009-01-14
FI20030379A0 (fi) 2003-03-14
WO2004080456A1 (en) 2004-09-23
US8673280B2 (en) 2014-03-18
JP2006520369A (ja) 2006-09-07
JP2011057708A (ja) 2011-03-24
DK1603559T3 (da) 2008-06-23
AU2004218944A1 (en) 2004-09-23
PL1603559T3 (pl) 2008-07-31
US20130041006A1 (en) 2013-02-14
ES2299823T3 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
Deng et al. Rapid glucocorticoid feedback inhibition of ACTH secretion involves ligand-dependent membrane association of glucocorticoid receptors
Bromati et al. UPR induces transient burst of apoptosis in islets of early lactating rats through reduced AKT phosphorylation via ATF4/CHOP stimulation of TRB3 expression
US8673280B2 (en) Pharmaceutical composition for intracellar acidification with cis-urocanic acid
US9592217B2 (en) Method for treating skin inflammatory diseases
IL303410A (en) Jack inhibitor with vitamin D analogue for the treatment of skin diseases
Yue et al. The promotion of liver regeneration in mice after a partial hepatectomy as a result of the modulation of macrophage activation by dexmedetomidine
EP2968209B1 (en) Metadichol r liquid and gel nanoparticle formulations
Mirjana et al. The rat acute-phase protein α2-macroglobulin plays a central role in amifostine-mediated radioprotection
Peralta et al. CD56bright cells increase expression of α4 integrin at ovulation in fertile cycles
EP2861228B1 (en) Compounds for treating inflammation and pain
US12005067B2 (en) JAK inhibitor with a vitamin D analog for treatment of skin diseases
Oukessou et al. The effect of feed quality on the kinetic disposition of orally administered triclabendazole in sheep
Goy-Thollot et al. The effects of 10% hypertonic saline, 0.9% saline and hydroxy ethyl starch infusions on hydro-electrolyte status and adrenal function in healthy conscious dogs
JP2664790B2 (ja) 紅斑抑制用の外用抗炎症剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOCIS PHARMA OY, FINLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEINO, LASSE;LAIHIA, JARMO;SIGNING DATES FROM 20050503 TO 20050504;REEL/FRAME:017023/0738

Owner name: BIOCIS PHARMA OY, FINLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEINO, LASSE;LAIHIA, JARMO;REEL/FRAME:017023/0738;SIGNING DATES FROM 20050503 TO 20050504

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20201120